课题基金 / 基金详情

Automation of the in vitro Micronucleus Assay

Automation of the in vitro Micronucleus Assay
体外微核测定的自动化
批准号:
6442812
负责人:
STEPHEN D DERTINGER
金额:
$9.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-06-01 至 2002-11-30

项目摘要

项目成果

STEPHEN D DERTINGER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The in vitro nucleus test is increasingly being used as an alternative to the more costly and time consuming in vitro chromosome aberration assay as a screen for detecting a chemical's genotoxic potential (aneugenic or clastogenic activity which are associated with disorders such as Down's Syndrome, cancers, etc.) Micronucleus measurements are made using the time-consuming and tedious process of microscopic inspection. No definitive and widely-accepted automated approach has come into use. During Phase I, we will investigate the use of flow cytometry to enumerate micronuclei in mouse lymphoma L5178 cells. This cell line is used in a commonly performed forward mutation assays (i.e., thymidine kinase locus) required by regulatory agencies world-wide. These cells offer the potential to develop an assay where the cells are treated and subsequently split between micronucleus and mutation endpoints, thereby minimizing plasticware, test article, and time requirements. Studies will focus on identifying gating and fluorescent staining procedures to discriminate bodies and mitotic chromosomes from true micronucleus events. Long range, the automated scoring procedures developed can be extended to the analysis of micronuclei in human lymphocytes. Some of these applications may include: 1) assessing the genotoxicity of pharmaceuticals. 2) identifying the individuals hypersensitive in particular genotoxin, 3) evaluating compounds or diets protective against genetic damage and 4) measurement of DNA damage in a population following a radiation and/or chemical accident. PROPOSED COMMERCIAL APPLICATION: The successful development of this methodology will enable Litron Laboratories to become an expert testing facility, capable of high throughput screening which identifies agents that cause cytogenetic damage. Furthermore, the extension of this methodology to the analysis of human blood lymphocytes and into kit format represents other significant areas of commercial opportunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Validation of a Rodent Mutagenicity Assay
  • 批准号:
    8197945
  • 项目类别:
  • 资助金额:
    $68.81万
  • 财政年份:
    2010
  • 负责人:
    STEPHEN D DERTINGER
  • 依托单位:
Validation of a Rodent Mutagenicity Assay
  • 批准号:
    7803927
  • 项目类别:
  • 资助金额:
    $34.83万
  • 财政年份:
    2010
  • 负责人:
    STEPHEN D DERTINGER
  • 依托单位:
Validation of a Rodent Mutagenicity Assay
  • 批准号:
    8070097
  • 项目类别:
  • 资助金额:
    $71.91万
  • 财政年份:
    2010
  • 负责人:
    STEPHEN D DERTINGER
  • 依托单位:
Versatile Mutation Assay Based on the Pig-A Locus
  • 批准号:
    7692880
  • 项目类别:
  • 资助金额:
    $38.57万
  • 财政年份:
    2008
  • 负责人:
    STEPHEN D DERTINGER
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: